- Bio-XCell has signed a CP with Stelis Biopharma (formerly Agila Biotech) and GE Healthcare Life Sciences to advance bioprocessing manufacturing capability and expertise at Bio-XCell's Biotechnology Park.
Malaysia, 21st October 2013 - Malaysian Bio-XCell, Stelis Biopharma and GE Healthcare Life Sciences today signed a Collaboration Proposal (CP) to explore the development of bioprocessing manufacturing capability and expertise at Bio-XCell's Biotechnology Park, Malaysia's premier Biotechnology Park and Ecosystem for industrial and healthcare biotechnology. Stelis, who signed a $34.4 million build-and-lease agreement with Malaysian Bio-XCell in March 2013, will explore the use of GE Healthcare's single-use bioprocessing technologies at its manufacturing facility at the Biotechnology Park. In addition, all three parties will explore opportunities to collaborate on establishing an advanced bioprocess training program in Malaysia.
"As a managed park, we aim to provide clients with a range of value added benefits and forging the strategic alliance with GE Healthcare enables key biotechnology players like Stelis to connect to the ecosystem" said Rizatuddin Ramli, CEO, Malaysian Bio-XCell.
Dr. Anand Iyer, CEO, Stelis Biopharma, commenting on the collaboration with Bio-XCell and GE stated that, "This collaboration would be a paradigm shift in how companies in emerging markets would build and operate next generation biomanufacturing facilities." He further stated that, 'This facility would play a key role in helping Malaysia's Bio-economy Transformation Program."
The CP combines Bio-XCell's strategy to create a favorable environment for industrial and healthcare biotechnology, with Stelis' expertise in biomanufacturing and GE's capabilities in world-class technologies for bioprocessing and in training.
GE Healthcare has over 20 years' experience in providing training in the latest technologies and strategies for bioprocess development and manufacturing with its global FAST Trak programs, which are specifically designed to help biopharmaceutical manufacturers maximize efficiency and bring product to market faster.
Olivier Loeillot, General Manager of Enterprise Solutions, GE Healthcare Life Sciences said, "We're delighted to be signing this CP with Bio-XCell and Stelis which underlines our vision of helping our customers accelerate the development of state-of-the-art, efficient biopharmaceutical manufacturing capabilities in order to meet the rising global demand for these live-saving medicines."
Bio-XCell's Biotechnology Park is Malaysia's premier Biotechnology Park and Ecosystem for industrial and healthcare biotechnology. Tenants of the Bio-XCell Biotechnology Park will benefit from the ecosystem enabled by Bio-XCell. The ecosystem includes the provision of specialised utilities required for biomanufacturing such as chilled water, industrial steam and waste water management via the Central Utilities Facility (CUF) which will be offered on a pay-per-use basis. To date a total investment of RM230 million has been spent to create the ecosystem and these on-going talks demonstrates the seriousness of Bio-XCell's commitment to attract leading biotech companies from around the world.
About Bio-XCell
Bio-XCell, a biotechnology park and ecosystem dedicated to healthcare and industrial biotechnology is being developed by Malaysian Bio-XCell Sdn Bhd, a joint venture company formed between Malaysian Biotechnology Corporation and property developer UEM Sunrise Berhad (formerly known as UEM Land Berhad) in 2009. Bio-XCell is strategically located on 160 acres in Nusajaya, within the Iskandar region of Johor, Malaysia, and close to the border with Singapore providing global connectivity through a network of five seaports and two international airports, all within 59 km. Bio-XCell offers a conducive environment for industrial and healthcare biotechnology. As a managed park, Bio-XCell will provide its clients and investors with a range of value added benefits including comprehensive infrastructure, high speed internet access, park maintenance and security as well as core facilities to nurture the ecosystem. Key facilities of the park include the Central Hub and Central Utilities Facility (CUF). The Central Hub is a multipurpose complex featuring a business centre, auditorium, lab & office space as well as amenities such as F&B and retail outlets. The CUF will provide specialised utilities for biomanufacturing to the park's clients. Clients have options to locate their manufacturing operations at one of the ready-built standard shell buildings or customise their own facility on one of the land plots available at the park. The park's global clients include Biocon (India) whose biologics facility will represent the largest insulin production plant in Asia, as well as Stelis Biopharma (formerly known as Agila Biotech (India)), METabolicEXplorer (France) and Glycos Biotechnologies (USA). Bio-XCell aspires to be a catalyst in biotechnology ecosystem in Iskandar Malaysia, with some 3,000 job opportunities expected to be created from its operation in the park. For more details or leasing inquiries, visit: http://www.bio-xcell.my
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients.
For our latest news, please visit http://newsroom.gehealthcare.com.
About Stelis Biopharma / Strides Arcolab Ltd.
Stelis Biopharma (Malaysia) Sdn Bhd (formerly known as Agila Biotech (Malaysia) Sdn Bhd), is a wholly owned subsidiary of Stelis Biopharma Private Limited, India (formerly known as Agila Biotech Private Limited, India), a wholly owned subsidiary of Strides Arcolab Limited, India.
Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of pharmaceutical products.
The Company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.
Additional information is available at the company's website at www.stridesarco.com.
Media Contacts:
Dzalman Dato' Zainal
Senior Manager - Strategic Communications & Stakeholder Relations
Contact: +603 2116 8555 (office)
+6012 220 5569
Email: [email protected]
Dhena Doraisamy
Senior Manager - Marketing, Branding & Publications
Contact: +603 2116 8555 (office)
+6012 641 1189
Email: [email protected]
Mirielle Ranade
GE Healthcare, ASEAN Communications
Contact: +65 9118 2214
Email: [email protected]
Dr. Val Jones
GE Healthcare, Global Media Relations
Contact: +44 7917 175 192
Email: [email protected]
For Stelis Biopharma / Strides
Dr. Anand Iyer, CEO -- Stelis Biopharma
Contact: +91 80 6784 0105
Mr. Kannan N: +91 98450 54745
(Investors)
PR Consultancy - Weber Shandwick
Kaveri Mandanna: +91 90089 59697
Email: [email protected]
Mahesh Nair: +91 98803 76648
Email: [email protected]
Zatalini - Zulkiply
[email protected]
business unit
tags